Provided interim Phase I/IIa update on clonal neoantigen reactive T cells in advanced NSCLC and melanoma Improved VELOS™ manufacturing process delivering higher cNeT doses Protocols updated to evaluate the benefit of enhanced host conditioning, with further data expected in 2H 2024 Strong cash position of $131.5 million supports operations through 2025 LONDON, April 04, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc... Read More

Improved VELOS™ manufacturing process delivering higher cNeT doses Protocols updated to evaluate the benefit of enhanced host conditioning, with further data expected in 2H 2024 First three patients dosed in CHIRON and THETIS with enhanced host chemo-conditioning, along with IL-2 aligned to standard TIL therapy, show improved cNeT persistence and engraftment LONDON, April 04, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics... Read More

LONDON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today announced that the Company will be presenting at the following conference: 10th Annual Immuno-Oncology 360 Conference (IO360) Speaker: Sergio Quezada, PhD, Chief Scientific Officer Presentation:... Read More

LONDON, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today announced publication of a ‘Comment’ in Nature Cancer that outlines the vast potential of neoantigen immunogenicity prediction, discusses current limitations in the field that limit performance,... Read More

On track to dose 15-20 patients with higher dose cNeT by year-end 2023 Clinical and translational science data update from the ongoing Phase I/IIa trials in NSCLC and melanoma expected in Q1 2024 with additional data available in mid-2024 Strong cash position of $140 million supports operations through 2025 LONDON, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical... Read More

LONDON, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today disclosed that the Company received notice on September 20, 2023 from the Nasdaq Stock Market LLC (“Nasdaq”) that the Company is not currently in compliance with the $1.00 minimum bid price... Read More

Clinical and translational science data expected in the fourth quarter of 2023 from the ongoing Phase I/IIa trials in NSCLC and melanoma neoRanker™ immunogenicity prediction module of PELEUS™ increases the likelihood of identifying multiple memory T cell responses Strong cash position of $144 million supports operations through 2025 LONDON, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a... Read More

LONDON, June 12, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies to treat solid tumors, today announced that the Company will be taking part in the following conferences in June: SAE Media Group Inaugural Cell and Gene Therapy Conference, London, United Kingdom Sergio Quezada, PhD, Chief Scientific Officer, will... Read More

Phase I/IIa clinical trials in NSCLC and melanoma progressing with additional clinical and translational science data expected in the fourth quarter of 2023 Strong cash position of $158.5 million supports operations into mid-2025 LONDON, May 10, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal... Read More

LONDON, May 10, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today announced that the Company’s new AI application, trained with proprietary real-world data, outperformed current AI and non-AI state-of-the-art methods for neoantigen immunogenicity prediction in... Read More

LONDON, April 25, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today disclosed that the Company received notice on April 21, 2023 from the Nasdaq Stock Market LLC (“Nasdaq”) that the Company is not currently in compliance with the $1.00 minimum bid price... Read More

Patent broadly covers technology to select neoantigens that are presented by HLA molecules determined to be present in a patient’s tumor Patent applies to any modality, including vaccine and autologous T cell therapy LONDON, April 25, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies to treat solid tumors, today... Read More

LONDON, April 17, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies to treat solid tumors, today announced that Dr. Iraj Ali, Chief Executive Officer, and Dr. Ed Samuel, EVP, Technical Operations, will participate in a fireside chat at Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit on... Read More

Demonstrated early proof-of-concept for cNeT therapy in heavily pre-treated advanced NSCLC patients Exhibited power of translational science platform by correlating anti-tumor activity of cNeT with targeting of clonal neoantigens Strong cash position of $173.3 million supports operations into mid-2025 LONDON, March 07, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical... Read More

LONDON, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies to treat solid tumors, today announced that Dr. Iraj Ali, Chief Executive Officer, will present at the 41 st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023, at 8:15 am PST. The event will be held at the Westin St. Francis Hotel... Read More

Early proof-of-concept data support durable clinical benefit including confirmed partial response and stable disease in heavily pre-treated patients with advanced NSCLC Safety and tolerability profile potentially expands opportunity to include patients ineligible for high dose lymphodepletion or high dose IL-2 Mechanism of action informed by translational science platform’s capability to correlate cNeT with anti-tumor... Read More

Durable partial response (PR) and stable disease (SD) achieved in heavily pre-treated non-small cell lung cancer (NSCLC) patients dosed with cNeT monotherapy Updated interim Phase I/II results show encouraging safety and tolerability profile with potential for deep and durable responses in NSCLC with cNeT and reduced-dose lymphodepletion and IL-2 Company to host a conference call and webcast on December 6, 2022 at 8:00am ET... Read More